US2021330625A1PendingUtilityA1

Lipid formulations containing bioactive fatty acids

74
Assignee: SCIADONICS INCPriority: Nov 25, 2015Filed: Jul 7, 2021Published: Oct 28, 2021
Est. expiryNov 25, 2035(~9.3 yrs left)· nominal 20-yr term from priority
Inventors:Alvin Berger
A23L 33/12A61K 45/06A23V 2002/00A61K 31/202
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions containing defined ratios of 5,11,14-eicosatrienoic acid to one or more of: 5, 9, 12-octadecatrienoic acid; 7, 11, 14-eicosatrienoic acid; 5, 8, 11, 14-eicosatetraenoic acid; 9, 12-octadecadienoic acid; 9-octadecenoic acid; 14-methylhexadecanoic acid; 11, 14 eicosadienoic acid, 5, 9-octadecadienoic acid; 5, 11-octadecadienoic acid; 9, 12, 15-octadecatrienoic acid; 5,8,11,14,17-eicosapentaenoic acid; 7,10,13,16,19-docosapentaenoic acid; and 4,7,10,13,16,19-docosahexaenoic acid.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A lipid formulation comprising an effective amount of 5,11,14-eicosatrienoic acid, wherein said lipid formulation is suitable for human consumption and one or more of the following properties:
 a) the formulation comprises 5, 9, 12-octadecatrienoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid: 5, 9, 12-octadecatrienoic acid is selected from the group consisting of 1:1 to 10:1, 1:1 to 5:1, 1:1 to 3:1, 1.5:1 to 2.5:1, 1.8:1 to 2.2:1, 1:2 to 1:20, 1:2 to 1:10, and 1:2 to 1:7;   b) the formulation comprises 7, 11, 14-eicosatrienoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid: 7, 11, 14-eicosatrienoic acid is selected from the group consisting of 3.5:1 to 6.5:1, 4:1 to 6:1, and 4.5:1 to 5.5:1;   c) the formulation comprises at least trace amounts of an acid selected from the group consisting of abietic acid, pimaric acid and 5, 9, 12, 15-octadecatetraenoic acid, in combination with 5,11,14-eicosatrienoic acid,   d) the formulation comprises 5, 8, 11, 14-eicosatetraenoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid: 5, 8, 11, 14-eicosatetraenoic acid is selected from the group consisting of 1:1 to 25:1, 3:1 to 25:1, 10:1 to 25:1, 1:1 to 10:1, and 3:1 to 10:1;   e) the formulation comprises 14-methylhexadecanoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid: 14-methylhexadecanoic acid is selected from the group consisting of 1:1 to 25:1, 1:1 to 10:1, 2:1 to 8:1, 3:1 to 7:1 and 4:1 to 6:1;   f) the formulation comprises 9, 12-octadecadienoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid: 9, 12-octadecadienoic acid is selected from the group consisting of 1:1 to 25:1, 2:1 to 25:1, 5:1 to 25:1, 10:1 to 25:1, 1:1 to 20:1, 2:1 to 20:1, 5:1 to 20:1, 10:1 to 20:1, 1:1 to 10:1, 2:1 to 10:1, 5:1 to 10:1, 1:1 to 1:25, 1:1 to 1:10, 1:1 to 1:5, 1:1 to 1:3 and 1:1 to 2.5:1;   g) the formulation comprises 9-octadecenoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid: 9, 12-octadecadienoic acid is selected from the group consisting of 1:1 to 25:1, 2:1 to 25:1, 5:1 to 25:1, 10:1 to 25:1, 1:1 to 20:1, 2:1 to 20:1, 5:1 to 20:1, 10:1 to 20:1, 1:1 to 10:1, 2:1 to 10:1, 5:1 to 10:1, 1:5 to 5:1, 1:4 to 4:1, 1:3 to 3:1, 1:2 to 2:1, and 1:1.5 to 1.5:1;   h) the formulation comprises 5, 9-octadecadienoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid: 5, 9-octadecadienoic acid is selected from the group consisting of 1:1 to 1:10, 1:2 to 1:8, 1:3 to 1:7, and 1:4 to 1:6;   i) the formulation comprises 5, 11-octadecadienoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid: 5, 11-octadecadienoic acid is selected from the group consisting of 1:1 to 10:1, 1:1 to 5:1, 1:1 to 4:1, 1:1 to 3:1, 1:1 to 1:2:1, 1:2 to 5:1, and 1:2 to 1:4;   j) the formulation comprises 5,8,11,14,17-eicosapentaenoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid: 5,8,11,14,17-eicosapentaenoic acid is selected from the group consisting of 20:1 to 1:20, 10:1 to 1:10, 5:1 to 1:5, 3:1 to 1:3, 1:1 to 1:20, 1:1 to 1:10, 1:1 to 1:5, 1:1 to 1:3, 20:1 to 1:1, 10:1 to 1:1, 5:1 to 1:1, and 3:1 to 1:1;   k) the formulation comprises 4,7,10,13,16,19-docosahexaenoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid: 4,7,10,13,16,19-docosahexaenoic acid is selected from the group consisting of 20:1 to 1:20, 10:1 to 1:10, 5:1 to 1:5, 3:1 to 1:3, 1:1 to 1:20, 1:1 to 1:10, 1:1 to 1:5, 1:1 to 1:3, 20:1 to 1:1, 10:1 to 1:1, 5:1 to 1:1, and 3:1 to 1:1;   l) the formulation comprises 7,10,13,16,19-docosapentaenoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid: 7,10,13,16,19-docosapentaenoic acid is selected from the group consisting of 20:1 to 1:20, 10:1 to 1:10, 5:1 to 1:5, 3:1 to 1:3, 1:1 to 1:20, 1:1 to 1:10, 1:1 to 1:5, 1:1 to 1:3, 20:1 to 1:1, 10:1 to 1:1, 5:1 to 1:1, and 3:1 to 1:1;   m) the formulation comprises 11, 14 eicosadienoic acid (20:2 n-6), wherein the ratio of 5, 11,14-eicosatrienoic acid to 11, 14 eicosadienoic acid (20:2 n-6) is selected from the group consisting of from 1:1 to 10:1, 1:1 to 5:1, 1:1 to 3:1 , 1:1 to 2.5:1, 1.5: 1 to 5:1, 1.5:1 to 3:1, 1.5:1 to 2.5:1, and 1.5:1 to 2:1; and   n) the formulation comprises gammalinolenic acid (6, 9, 12 18:3) and/or dihommogammalinolenic acid (8,11,14 20:3), wherein the ratio of 5,11,14-eicosatrienoic acid to gammalinolenic acid (6, 9, 12 18:3) and/or dihommogammalinolenic acid (8,11,14 20:3) is selected from the group consisting of from 1:1 to 10:1, 1:1 to 5:1, 1:1 to 3:1 , 1:1 to 2.5:1, 1.5: 1 to 5:1, 1.5:1 to 3:1, 1.5:1 to 2.5:1, and 1.5:1 to 2:1.   
     
     
         2 . The lipid formulation of  claim 1 , wherein said lipid formulation has two or more of properties (a) to (m). 
     
     
         3 . The lipid formulation of  claim 1 , wherein said lipid formulation has three or more of properties (a) to (m). 
     
     
         4 . The lipid formulation of  claim 1 , wherein said lipid formulation has four or more of properties (a) to (m). 
     
     
         5 . The lipid formulation of  claim 1 , wherein said lipid formulation has five or more of properties (a) to (m). 
     
     
         6 . The lipid formulation of  claim 1 , wherein said lipid formulation has six or more of properties (a) to (m). 
     
     
         7 . The lipid formulation of  claim 1 , wherein said lipid formulation has seven or more of properties (a) to (m). 
     
     
         8 . The lipid formulation of  claim 1 , wherein said lipid formulation has eight or more of properties (a) to (m). 
     
     
         9 . The lipid formulation of  claim 1 , wherein said lipid formulation has nine or more of properties (a) to (m). 
     
     
         10 . The lipid formulation of  claim 1 , wherein said lipid formulation has ten or more of properties (a) to (m). 
     
     
         11 . The lipid formulation of  claim 1 , wherein said lipid formulation has eleven or more of properties (a) to (m). 
     
     
         12 . The lipid formulation of  claim 1 , wherein said lipid formulation has property (a). 
     
     
         13 . The lipid formulation of  claim 1 , wherein said lipid formulation has property (b). 
     
     
         14 . The lipid formulation of  claim 1 , wherein said lipid formulation has property (c). 
     
     
         15 . The lipid formulation of  claim 1 , wherein said lipid formulation has properties (a) and (b). 
     
     
         16 . The lipid formulation of  claim 1 , wherein said lipid formulation has properties (a), (b) and (c). 
     
     
         17 . The lipid formulation of  claim 1 , wherein said lipid formulation has property (d). 
     
     
         18 . The lipid formulation of  claim 1 , wherein said lipid formulation has property (e). 
     
     
         19 . The lipid formulation of  claim 1 , wherein said lipid formulation has property (h). 
     
     
         20 . The lipid formulation of  claim 1 , wherein said lipid formulation has property (i).

Join the waitlist — get patent alerts

Track US2021330625A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.